DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
National Institutes of Health Clinical Center (CC)
Mayo Clinic
University of Southern California
Yale University